25 May 2021
Archimica invests 1,3 Mio. Euro in Expansion of Process Development Capacity
Archimica has started the operation of its expanded development laboratories at its Lodi (Italy) site. A recent investment has more than doubled the company´s capabilities to realize API and GMP Building Block custom process development and manufacturing projects from April 2021 on. The investment comprises chemical and analytical capabilities, with a total investment volume of 1,3 Mio. Euro.
“With this expansion our integrated process development and manufacturing team can use significantly expanded laboratory capacity applying Archimica´s unique chemical technology portfolio to the benefit of our customers worldwide. Archimica’s broad permit and state-of-the-art environmental protection facilities enable us to industrialize products and processes with the most challenging reagents and reactions known”, said Ralf Pfirmann, Executive Chairman of Archimica.
Archimica is a leading organization specialized since more than 70 years in active pharmaceutical ingredients (APIs) development and manufacture for the benefit of customers and patients worldwide. It operates its site in Lodi, Italy in compliance with the most recent GMP guidelines and has been successfully inspected by US-FDA, EMA and numerous other regulatory agencies.
Archimica offers a range of standard care generic APIs in a broad range of therapeutic areas as well as custom synthesis of late stage intermediates and APIs for the innovative and the generic pharmaceutical industry. Its offering covers highly flexible, agile small clinical stage to continuously improving large commercial manufacturing as well as process development, analytical, quality and regulatory services.
Archimica employs more than 115 staff members which achieve annual revenues of more than 30 Mio. €. Since 2019 Archimica is a fully owned portfolio company of Livia Corporate Development SE.
For more information, visit https://www.archimica.com.